Sanofi said that Sarclisa, its treatment for plasma cell cancer, was recommended for EU approval by the European Medicines Agency. The agency's Committee for Medicinal Products for Human Use ...

RFK Jr. has developed a reputation as a vaccine skeptic and pushed conspiracy theories including one linking vaccines to ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

Everi Holdings Inc. ("Everi" or the "Company"), a premier provider of land-based and digital casino gaming content and products, financial technology, player loyalty solutions, and bingo, announced ...

POET Technologies Inc. ("POET" or the "Company") , the designer and developer of the POET Optical Interposertm, Photonic Integrated Circuits (PICs) and light sources for the data center, ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Published ...

Grifols (GRFS) stock gains as banks aim to finalize an €11B debt package for Brookfield's (BAM) plan to take the healthcare ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Innovative Industrial Properties Inc. 9% Cum. Conv. Redeem. Pfd. Series A 0.34% Digital Realty Trust Inc. 5.25% Cum. Conv. Pfd. Series J 0.15% Digital Realty Trust Inc. 5.2% Cum. Redeem. Pfd ...